Literature DB >> 26681712

Racial Differences in and Prognostic Value of Biomarkers of Hyperglycemia.

Christina M Parrinello1, A Richey Sharrett1, Nisa M Maruthur2, Richard M Bergenstal3, Morgan E Grams4, Josef Coresh2, Elizabeth Selvin5.   

Abstract

OBJECTIVE: We compared levels and associations of traditional (fasting glucose, HbA1c) and nontraditional (fructosamine, glycated albumin, and 1,5-anhydroglucitol [1,5-AG]) biomarkers of hyperglycemia with incident cardiovascular disease (CVD), incident end-stage renal disease (ESRD), and prevalent retinopathy in black and white adults. RESEARCH DESIGN AND METHODS: We included 10,373 participants without (8,096 white, 2,277 black) and 727 with diagnosed diabetes (425 white, 302 black) from the Atherosclerosis Risk in Communities (ARIC) Study. We used Cox proportional hazards models to compare hazards ratios of CVD and ESRD among blacks and whites from baseline (1990-1992) through 2012. We compared the odds ratios (from logistic regression) of retinopathy among blacks and whites. We tested for the interaction of each biomarker with race.
RESULTS: Median values of biomarkers were higher among blacks versus whites (all P < 0.001). Relative risks for each biomarker with incident CVD and ESRD, and odds ratios for each biomarker with prevalent retinopathy, were similar by race (all P values for interaction by race >0.10).
CONCLUSIONS: The prognostic value of HbA1c, fructosamine, glycated albumin, and 1,5-AG with incident CVD, incident ESRD, and prevalent retinopathy were similar by race. Our results support similar interpretation of HbA1c and nontraditional biomarkers of hyperglycemia among black and whites with respect to long-term complications.
© 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26681712      PMCID: PMC4806772          DOI: 10.2337/dc15-1360

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  41 in total

Review 1.  (2) Classification and diagnosis of diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2015-01       Impact factor: 19.112

2.  Fructosamine and Glycated Albumin and the Risk of Cardiovascular Outcomes and Death.

Authors:  Elizabeth Selvin; Andreea M Rawlings; Pamela L Lutsey; Nisa Maruthur; James S Pankow; Michael Steffes; Josef Coresh
Journal:  Circulation       Date:  2015-05-28       Impact factor: 29.690

3.  Diagnosis of diabetes mellitus using HbA1c in Asians: relationship between HbA1c and retinopathy in a multiethnic Asian population.

Authors:  Charumathi Sabanayagam; Eric Y H Khoo; Weng Kit Lye; M Kamran Ikram; Ecosse L Lamoureux; Ching Yu Cheng; Maudrene L S Tan; Agus Salim; Jeannette Lee; Su-Chi Lim; Subramaniam Tavintharan; Ah-Chuan Thai; Derrick Heng; Stefan Ma; E Shyong Tai; Tien Y Wong
Journal:  J Clin Endocrinol Metab       Date:  2014-11-06       Impact factor: 5.958

Review 4.  Beyond HbA1c and glucose: the role of nontraditional glycemic markers in diabetes diagnosis, prognosis, and management.

Authors:  Christina M Parrinello; Elizabeth Selvin
Journal:  Curr Diab Rep       Date:  2014       Impact factor: 4.810

5.  Association of 1,5-anhydroglucitol with diabetes and microvascular conditions.

Authors:  Elizabeth Selvin; Andreea M Rawlings; Morgan Grams; Ronald Klein; Michael Steffes; Josef Coresh
Journal:  Clin Chem       Date:  2014-09-08       Impact factor: 8.327

6.  Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Elizabeth Selvin; Andreea M Rawlings; Morgan Grams; Ronald Klein; A Richey Sharrett; Michael Steffes; Josef Coresh
Journal:  Lancet Diabetes Endocrinol       Date:  2014-01-15       Impact factor: 32.069

7.  Association of 1,5-Anhydroglucitol With Cardiovascular Disease and Mortality.

Authors:  Elizabeth Selvin; Andreea Rawlings; Pamela Lutsey; Nisa Maruthur; James S Pankow; Michael Steffes; Josef Coresh
Journal:  Diabetes       Date:  2015-09-22       Impact factor: 9.461

8.  Serum fructosamine and glycated albumin and risk of mortality and clinical outcomes in hemodialysis patients.

Authors:  Tariq Shafi; Stephen M Sozio; Laura C Plantinga; Bernard G Jaar; Edward T Kim; Rulan S Parekh; Michael W Steffes; Neil R Powe; Josef Coresh; Elizabeth Selvin
Journal:  Diabetes Care       Date:  2012-12-18       Impact factor: 19.112

9.  No ethnic differences in the association of glycated hemoglobin with retinopathy: the national health and nutrition examination survey 2005-2008.

Authors:  Julie K Bower; Frederick L Brancati; Elizabeth Selvin
Journal:  Diabetes Care       Date:  2012-10-15       Impact factor: 19.112

10.  No racial differences in the association of glycated hemoglobin with kidney disease and cardiovascular outcomes.

Authors:  Elizabeth Selvin; Andreea M Rawlings; Richard M Bergenstal; Josef Coresh; Frederick L Brancati
Journal:  Diabetes Care       Date:  2013-05-30       Impact factor: 19.112

View more
  13 in total

1.  Effects of dietary carbohydrate on 1,5-anhydroglucitol in a population without diabetes: results from the OmniCarb trial.

Authors:  S P Juraschek; E R Miller; L J Appel; R H Christenson; F M Sacks; E Selvin
Journal:  Diabet Med       Date:  2017-07-09       Impact factor: 4.359

Review 2.  Haemoglobin A1c or Glycated Albumin for Diagnosis and Monitoring Diabetes: An African Perspective.

Authors:  J A George; R T Erasmus
Journal:  Indian J Clin Biochem       Date:  2018-05-03

3.  Are There Clinical Implications of Racial Differences in HbA1c? A Difference, to Be a Difference, Must Make a Difference.

Authors:  Elizabeth Selvin
Journal:  Diabetes Care       Date:  2016-08       Impact factor: 19.112

4.  Continuous Glucose Monitoring and Use of Alternative Markers To Assess Glycemia in Chronic Kidney Disease.

Authors:  Leila R Zelnick; Zona O Batacchi; Iram Ahmad; Ashveena Dighe; Randie R Little; Dace L Trence; Irl B Hirsch; Ian H de Boer
Journal:  Diabetes Care       Date:  2020-08-11       Impact factor: 19.112

Review 5.  Issues in Defining the Burden of Prediabetes Globally.

Authors:  Justin B Echouffo-Tcheugui; Andre P Kengne; Mohammed K Ali
Journal:  Curr Diab Rep       Date:  2018-09-19       Impact factor: 4.810

6.  Rationale and Design for a GRADE Substudy of Continuous Glucose Monitoring.

Authors:  Mary E Larkin; David M Nathan; Ionut Bebu; Heidi Krause-Steinrauf; William H Herman; John M Higgins; Margaret Tiktin; Robert M Cohen; Claire Lund; Richard M Bergenstal; Mary L Johnson; Valerie Arends
Journal:  Diabetes Technol Ther       Date:  2019-09-04       Impact factor: 6.118

Review 7.  Prediabetes and What It Means: The Epidemiological Evidence.

Authors:  Justin B Echouffo-Tcheugui; Elizabeth Selvin
Journal:  Annu Rev Public Health       Date:  2021-12-23       Impact factor: 21.981

8.  Factors associated with glycated albumin in adults without diabetes.

Authors:  Priscila Aparecida Corrêa Freitas; Mayana Kieling Hernandez; Joíza Lins Camargo
Journal:  Med Pharm Rep       Date:  2021-04-29

9.  Serum fructosamine and glycemic status in the presence of the sickle cell mutation.

Authors:  Ayo P Doumatey; Hermon Feron; Kenneth Ekoru; Jie Zhou; Adebowale Adeyemo; Charles N Rotimi
Journal:  Diabetes Res Clin Pract       Date:  2021-06-11       Impact factor: 8.180

10.  Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia.

Authors:  Bernd Richter; Bianca Hemmingsen; Maria-Inti Metzendorf; Yemisi Takwoingi
Journal:  Cochrane Database Syst Rev       Date:  2018-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.